Patent ID: 9101653
Filing Date: 2015-08-11
Classification: A61K,A61P,C12N,G01N

Abstract:
1. A vaccine comprising an effective amount of an isolated stable, biologically contained multivalent influenza virus comprising: i) 8 different gene segments including a PA viral gene segment, a PB1 viral gene segment, a mutant PB2 viral gene segment, a HA viral gene segment, a NA viral gene segment, a NP viral gene segment, a M (M1 and M2) viral gene segment, and a NS (NS1 and NS2) viral gene segment, ii) 8 different gene segments including a PA viral gene segment, a PB1 viral gene segment, a mutant PB2 viral gene segment, a HA viral gene segment, a NA (NA and NB) viral gene segment, a NP viral gene segment, a M (M1 and BM2) viral gene segment and a NS (NS1 and NS2) viral gene segment, or iii) 7 different gene segments including a PA viral gene segment, a PB1 viral gene segment, a mutant PB2 viral gene segment, a HEF viral gene segment, a NP viral gene segment, a M (M1 and CM2) viral gene segment, and a NS (NS1 and NS2) viral gene segment; wherein the mutant PB2 viral gene segment includes 5′ and 3′ incorporation sequences including 3′ or 5′ coding and non-coding incorporation sequences flanking a heterologous nucleotide sequence and does not include contiguous sequences corresponding to sequences encoding a functional PB2, and wherein the heterologous nucleotide sequence encodes a gene product that induces a prophylactic or therapeutic immune response to a pathogen.